Ari Baron, MD
Hematology-Oncology · San Francisco, CANPI 1013086420
Payments from drug & device makers
Across 1,454 payments — averaging $2118.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$850K
- E.r. Squibb & Sons, L.L.C.$604K
- Genentech, Inc.$338K
- AstraZeneca$243K
- Merck$191K
- Novartis$138K
- plus $716K from 54 others
Across 1 payment — averaging $236.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$237
What the payments were for
- Consulting fees$55,6258%
- Speaking & faculty fees$613,11687%
- Travel & lodging$12,0442%
- Food & beverage$23,4563%
- Education$5530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,080,074 in reported general payments places this provider in the 95th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 398 | $5,280,039 |
| Lupron DepotLeuprolide Acetate | 133 | $809,746 |
| KeytrudaPembrolizumab | 69 | $773,826 |
| RevlimidLenalidomide | 34 | $647,896 |
| LynparzaOlaparib | 38 | $622,037 |
| XtandiEnzalutamide | 54 | $600,150 |
| TagrissoOsimertinib Mesylate | 33 | $582,919 |
| BrukinsaZanubrutinib | 34 | $511,426 |
| OjjaaraMomelotinib Dihydrochloride | 17 | $468,779 |
| IdhifaEnasidenib Mesylate | 13 | $433,090 |
| ImbruvicaIbrutinib | 22 | $373,093 |
| XgevaDenosumab | 110 | $348,651 |
| Neulasta OnproPegfilgrastim | 53 | $328,705 |
| ZejulaNiraparib Tosylate | 16 | $296,673 |
| OpdivoNivolumab | 26 | $296,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $51,630 | $5,280,039398 claims |
| AstraZenecaLynparza, Tagrisso | $242,555 | $1,204,95571 claims |
| Bristol Myers SquibbRevlimid, Idhifa | $26,136 | $1,080,98647 claims |
| AbbVieLupron Depot, Venclexta, Creon | $97,413 | $1,038,938167 claims |
| MerckKeytruda | $190,780 | $773,82669 claims |
| GSKOjjaara, Zejula | $351 | $765,45233 claims |
| AmgenXgeva, Aranesp, Nplate | $21,488 | $645,713229 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $23,995 | $605,56366 claims |
| Beigene USA, Inc.Brukinsa | $62 | $511,42634 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $452 | $373,09322 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo | $604,213 | $296,22726 claims |
| NovartisPromacta, Gleevec | $137,915 | $271,89325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in San Francisco
- Jeffrey WolfSan Francisco$407K
- Bertrand TuanSan Francisco$120K
- Xiaolin ZhuSan Francisco$112
- Noah YoungerSan Francisco$0
- Travis ZackSan Francisco$0
- Evan WalkerSan Francisco$0
- Annabel FrankSan Francisco$0
- Sant ChawlaSanta Monica$10.8M
- James BerensonWest Hollywood$8.4M
- Lee RosenSanta Monica$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.